- Home
- CMCL vs CHRS Comparison
CMCL vs CHRS Comparison
Compare CMCL & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMCL | CHRS |
|---|---|---|
| Founded | 1992 | 2010 |
| Country | Jersey | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.3M | 291.5M |
| IPO Year | 2003 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CMCL | CHRS |
|---|---|---|
| Price | $23.53 | $1.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $28.00 | $5.51 |
| AVG Volume (30 Days) | 212.4K | ★ 1.3M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | N/A | ★ 1.43 |
| Revenue | N/A | N/A |
| Revenue This Year | $38.38 | $73.08 |
| Revenue Next Year | N/A | $30.94 |
| P/E Ratio | $10.88 | ★ $1.20 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.65 | $0.72 |
| 52 Week High | $38.75 | $2.62 |
Technical Indicators
Market Signals| Indicator | CMCL | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 44.04 | 50.70 |
| Support Level | $23.10 | $1.55 |
| Resistance Level | $24.49 | $1.78 |
| Average True Range (ATR) | 1.29 | 0.10 |
| MACD | 0.18 | 0.01 |
| Stochastic Oscillator | 48.88 | 57.58 |
Price Performance
Historical ComparisonAbout CMCL Caledonia Mining Corporation Plc
Caledonia Mining Corp PLC is a gold exploration, development, and mining company. The company's segment includes Blanket, South Africa, Bilboes Oxide mine, and E&E projects. The company generates the majority of its revenue from the Blanket project. The Blanket Mine is located in the south-west of Zimbabwe and operates at a depth of approximately 750 meters below the surface. The company's project includes Maligreen and Motapa.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.